Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump BioSpaceAn unnamed pharma filed a citizen petition in April seeking reforms to the way the FDA publicly releases rejection letters, alleging that the policy...Read full story pharminent July 9, 2026 (Last updated: July 9, 2026) BioSpace An unnamed pharma filed a citizen petition in April seeking reforms to the way the FDA publicly releases rejection letters, alleging that the policy… Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: NICE aims to cut funding for Amgen lung cancer drug LumykrasNext: GSK ends dementia alliance with Alector after setbacks Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
